245 related articles for article (PubMed ID: 23216744)
1. Maintenance of S-nitrosothiol homeostasis plays an important role in growth suppression of estrogen receptor-positive breast tumors.
Cañas A; López-Sánchez LM; Valverde-Estepa A; Hernández V; Fuentes E; Muñoz-Castañeda JR; López-Pedrera C; De La Haba-Rodríguez JR; Aranda E; Rodríguez-Ariza A
Breast Cancer Res; 2012 Dec; 14(6):R153. PubMed ID: 23216744
[TBL] [Abstract][Full Text] [Related]
2. Anterior gradient-2 plays a critical role in breast cancer cell growth and survival by modulating cyclin D1, estrogen receptor-alpha and survivin.
Vanderlaag KE; Hudak S; Bald L; Fayadat-Dilman L; Sathe M; Grein J; Janatpour MJ
Breast Cancer Res; 2010; 12(3):R32. PubMed ID: 20525379
[TBL] [Abstract][Full Text] [Related]
3. Keratinocyte growth factor (KGF) regulates estrogen receptor-alpha (ER-alpha) expression and cell apoptosis via phosphatidylinositol 3-kinase (PI3K)/Akt pathway in human breast cancer cells.
Chang HL; Sugimoto Y; Liu S; Wang LS; Huang YW; Ye W; Lin YC
Anticancer Res; 2009 Aug; 29(8):3195-205. PubMed ID: 19661335
[TBL] [Abstract][Full Text] [Related]
4. p53 status influences response to tamoxifen but not to fulvestrant in breast cancer cell lines.
Fernandez-Cuesta L; Anaganti S; Hainaut P; Olivier M
Int J Cancer; 2011 Apr; 128(8):1813-21. PubMed ID: 20549698
[TBL] [Abstract][Full Text] [Related]
5. Altered S-nitrosothiol homeostasis provides a survival advantage to breast cancer cells in HER2 tumors and reduces their sensitivity to trastuzumab.
Cañas A; López-Sánchez LM; Peñarando J; Valverde A; Conde F; Hernández V; Fuentes E; López-Pedrera C; de la Haba-Rodríguez JR; Aranda E; Rodríguez-Ariza A
Biochim Biophys Acta; 2016 Apr; 1862(4):601-610. PubMed ID: 26854735
[TBL] [Abstract][Full Text] [Related]
6. Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models.
Kuske B; Naughton C; Moore K; Macleod KG; Miller WR; Clarke R; Langdon SP; Cameron DA
Endocr Relat Cancer; 2006 Dec; 13(4):1121-33. PubMed ID: 17158758
[TBL] [Abstract][Full Text] [Related]
7. Interplay between estrogen receptor and AKT in estradiol-induced alternative splicing.
Bhat-Nakshatri P; Song EK; Collins NR; Uversky VN; Dunker AK; O'Malley BW; Geistlinger TR; Carroll JS; Brown M; Nakshatri H
BMC Med Genomics; 2013 Jun; 6():21. PubMed ID: 23758675
[TBL] [Abstract][Full Text] [Related]
8. Aromatase overexpression induces malignant changes in estrogen receptor α negative MCF-10A cells.
Wang J; Gildea JJ; Yue W
Oncogene; 2013 Oct; 32(44):5233-40. PubMed ID: 23178495
[TBL] [Abstract][Full Text] [Related]
9. Binding of anterior gradient 2 and estrogen receptor-α: Dual critical roles in enhancing fulvestrant resistance and IGF-1-induced tumorigenesis of breast cancer.
Li Z; Zhu Q; Chen H; Hu L; Negi H; Zheng Y; Ahmed Y; Wu Z; Li D
Cancer Lett; 2016 Jul; 377(1):32-43. PubMed ID: 27063095
[TBL] [Abstract][Full Text] [Related]
10. Heregulin controls ERα and HER2 signaling in mammospheres of ERα-positive breast cancer cells and interferes with the efficacy of molecular targeted therapy.
Fukui F; Hayashi SI; Yamaguchi Y
J Steroid Biochem Mol Biol; 2020 Jul; 201():105698. PubMed ID: 32404282
[TBL] [Abstract][Full Text] [Related]
11. AR collaborates with ERα in aromatase inhibitor-resistant breast cancer.
Rechoum Y; Rovito D; Iacopetta D; Barone I; Andò S; Weigel NL; O'Malley BW; Brown PH; Fuqua SA
Breast Cancer Res Treat; 2014 Oct; 147(3):473-85. PubMed ID: 25178514
[TBL] [Abstract][Full Text] [Related]
12. CSNK1G2 differently sensitizes tamoxifen-induced decrease in PI3K/AKT/mTOR/S6K and ERK signaling according to the estrogen receptor existence in breast cancer cells.
Nguyen Hoang AT; Hoe KL; Lee SJ
PLoS One; 2021; 16(4):e0246264. PubMed ID: 33861751
[TBL] [Abstract][Full Text] [Related]
13. Molecular basis for estrogen receptor alpha deficiency in BRCA1-linked breast cancer.
Hosey AM; Gorski JJ; Murray MM; Quinn JE; Chung WY; Stewart GE; James CR; Farragher SM; Mulligan JM; Scott AN; Dervan PA; Johnston PG; Couch FJ; Daly PA; Kay E; McCann A; Mullan PB; Harkin DP
J Natl Cancer Inst; 2007 Nov; 99(22):1683-94. PubMed ID: 18000219
[TBL] [Abstract][Full Text] [Related]
14. Andrographolide Exhibits Anticancer Activity against Breast Cancer Cells (MCF-7 and MDA-MB-231 Cells) through Suppressing Cell Proliferation and Inducing Cell Apoptosis via Inactivation of ER-α Receptor and PI3K/AKT/mTOR Signaling.
Tohkayomatee R; Reabroi S; Tungmunnithum D; Parichatikanond W; Pinthong D
Molecules; 2022 May; 27(11):. PubMed ID: 35684480
[TBL] [Abstract][Full Text] [Related]
15. The G protein-coupled receptor GPR30 inhibits proliferation of estrogen receptor-positive breast cancer cells.
Ariazi EA; Brailoiu E; Yerrum S; Shupp HA; Slifker MJ; Cunliffe HE; Black MA; Donato AL; Arterburn JB; Oprea TI; Prossnitz ER; Dun NJ; Jordan VC
Cancer Res; 2010 Feb; 70(3):1184-94. PubMed ID: 20086172
[TBL] [Abstract][Full Text] [Related]
16. ERBB2 influences the subcellular localization of the estrogen receptor in tamoxifen-resistant MCF-7 cells leading to the activation of AKT and RPS6KA2.
Pancholi S; Lykkesfeldt AE; Hilmi C; Banerjee S; Leary A; Drury S; Johnston S; Dowsett M; Martin LA
Endocr Relat Cancer; 2008 Dec; 15(4):985-1002. PubMed ID: 18824559
[TBL] [Abstract][Full Text] [Related]
17. ShRNA-mediated gene silencing of MTA1 influenced on protein expression of ER alpha, MMP-9, CyclinD1 and invasiveness, proliferation in breast cancer cell lines MDA-MB-231 and MCF-7 in vitro.
Jiang Q; Zhang H; Zhang P
J Exp Clin Cancer Res; 2011 May; 30(1):60. PubMed ID: 21595884
[TBL] [Abstract][Full Text] [Related]
18. MIBE acts as antagonist ligand of both estrogen receptor α and GPER in breast cancer cells.
Lappano R; Santolla MF; Pupo M; Sinicropi MS; Caruso A; Rosano C; Maggiolini M
Breast Cancer Res; 2012 Jan; 14(1):R12. PubMed ID: 22251451
[TBL] [Abstract][Full Text] [Related]
19. Signal transducer and activator of transcription 5b, c-Src, and epidermal growth factor receptor signaling play integral roles in estrogen-stimulated proliferation of estrogen receptor-positive breast cancer cells.
Fox EM; Bernaciak TM; Wen J; Weaver AM; Shupnik MA; Silva CM
Mol Endocrinol; 2008 Aug; 22(8):1781-96. PubMed ID: 18550772
[TBL] [Abstract][Full Text] [Related]
20. A novel taspine derivative, HMQ1611, inhibits breast cancer cell growth via estrogen receptor α and EGF receptor signaling pathways.
Zhan Y; Zhang Y; Liu C; Zhang J; Smith WW; Wang N; Chen Y; Zheng L; He L
Cancer Prev Res (Phila); 2012 Jun; 5(6):864-73. PubMed ID: 22496388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
